Q1 2026 Liquidia Corp Earnings Call Transcript
Key Points
- YUTREPIA is leading the growth of the inhaled prostacyclin category, with approximately 4,500 unique patient prescriptions and 3,750 patients started on therapy since launch.
- The company has established a profitable, self-funded business, delivering its third consecutive quarter of profitability with growing top line, bottom line, and cash reserves.
- Liquidia Corp (LQDA) is expanding its clinical programs, including the pivotal Phase 3 RESPIRE study of L606 and additional studies to broaden the opportunity for YUTREPIA.
- The company has achieved significant growth in net product sales, with a 44% sequential increase from the fourth quarter of 2025 to the first quarter of 2026.
- Liquidia Corp (LQDA) has a clear line of sight to at least $1 billion in net revenue by 2027, with multiple growth opportunities to sustain further growth well into the future.
- The company faces risks and uncertainties related to forward-looking statements and ongoing litigation, which could impact future results.
- There is a need for continued investment in sales force expansion and manufacturing capacity, which could strain resources.
- The market for PH-ILD is still underpenetrated, requiring significant efforts in education and awareness to drive growth.
- The company is now an income taxpayer, which could impact future profitability.
- There are challenges in transitioning patients from other therapies to YUTREPIA, requiring additional studies and data to support these efforts.
Good morning, and welcome to Liquidia Corporation first-quarter 2026 financial results and corporate update conference call. My name is Jonathan, and I will be your operator today. (Operator Instructions) Please note that today's call is being recorded.
And now I'd like to turn the call over to Jason Adair, Liquidia's Chief Business Officer. You may proceed.
Thank you, and good morning, everyone. It's my pleasure to welcome you to our first-quarter 2026 financial results and corporate update call. Joining me today are Dr. Roger Jeffs, Chief Executive Officer; Michael Kaseta, Chief Operating Officer and Chief Financial Officer; Dr. Rajeev Saggar, Chief Medical Officer; Scott Moomaw, Chief Commercial Officer; and Rusty Schundler, our General Counsel.
Before we begin, please note that today's discussion will include forward-looking statements, including statements regarding future results, product performance and ongoing clinical or commercial activities. These statements are subject to risks
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
